Boston, MA & Singapore - October 3, 2022 – AIM Biotech announced the launch of the organiX System, a lab tool to closely model human disease by adding vascularization and immune competence to organoids, spheroids and tumor biopsies. Adding vascularization and immune cells to a disease model creates a more defined and tunable microenvironment to more closely emulate the complexity of human physiology. This is all packaged together in an easy-to-use tool, designed around a universal plate format, so labs and researchers can more easily study diseases, more accurately predict success of investigational treatments and better predict optimal patient therapies.
“One of the missing links in organoid research has been the real-world effect of vascularization and immune cells,” said Jim McGorry, CEO of AIM Biotech. “Labs and research teams now have an elegant and simple-to-use tool that closely mimics the complex physiology of human disease in a recognizable and universally used plate that fits into existing workflow. The benefits include making it easier for drug developers to predict which therapies to bring into and through clinical trials and eventually aid healthcare providers in tailoring optimal treatments for patients.”
When applied to organoids and biopsies, conventional tissue culture methods do not simulate the natural human environment of nutrient perfusion and vascularization. This limits critical interactions with other essential cell types typically found in the body. Without a true-to-life microenvironment safety and efficacy data doesn’t accurately predict human response.
organiX addresses these shortcomings by allowing the culture of organoids in a vascularized microenvironment with other critical cell types, thereby creating a far more realistic and physiologically accurate way to test the effectiveness of new therapies using human, even patient-specific tissue, to establish dosing and efficacy.
The organiX platform is specifically designed to host human tissue biopsies or organoids of up to 2 mm in diameter. These tissue models are increasingly adopted by clinicians and biotech organizations, and have the potential to revolutionize the assessment of conventional and experimental approaches to cancer treatment. The promise is for researchers to test and co-culture cells in a more physiologically meaningful arrangement to better predict human response and compliment genetic data.
McGorry continues, “Instead of just adding drugs to organoids without realistic microenvironments, organiX enables any investigator to easily add functional vasculature and relevant cell types like immune cells to patient-specific tumor biopsies or organoids. The treated biopsies or organoids can be retrieved intact along with the surrounding microenvironment for histological or advanced genomic/proteomic analysis.”
AIM Biotech has acquired the worldwide exclusive license to this technology from A*STAR Singapore’s Institute of Molecular and Cell Biology (IMCB). The organiX platform is manufactured by AIM Biotech in Singapore and is available directly from the company and its official distributors.
Click here to learn more about organiX.
AIM Biotech is a biotechnology company at the forefront of transforming drug discovery into a more targeted, predictable and less expensive endeavor. The company’s patented microfluidic devices and assays in critical therapeutic areas bring actual human physiological context to drug discovery and cancer therapy selection, enabling insights not previously possible through conventional approaches. AIM Biotech is located in Singapore and Boston, MA.
